("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, for chronic weight management in Chinese adults with overweight or obesity
Verification of vagotomy with FluoroGold To confirm vagotomy, each mouse received an IP injection of FluoroGold (0.8 mg/0.4 ml saline
- Registro INVIMA SD2020-0004506
Results Twenty-nine patients finished the protocol
Precautions If you have a medical condition, or are taking medications, consult your healthcare professional before using this product